Free Trial

ProQR Therapeutics (PRQR) News Today

ProQR Therapeutics logo
$1.70 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.80 +0.10 (+5.88%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRQR Latest News

ProQR Therapeutics stock logo
Millennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR)
Millennium Management LLC boosted its stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 1,864.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,827,280 shares of the biopharmaceutical company's stock a
ProQR Therapeutics stock logo
Woodline Partners LP Buys Shares of 3,557,001 ProQR Therapeutics (NASDAQ:PRQR)
Woodline Partners LP acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,557,001 shares of the biopharmaceutical company'
ProQR Therapeutics stock logo
Point72 Asset Management L.P. Takes Position in ProQR Therapeutics (NASDAQ:PRQR)
Point72 Asset Management L.P. acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,491,275 shares of the biopharmaceutical company's stock, valued at approxim
ProQR Therapeutics stock logo
FY2025 EPS Forecast for ProQR Therapeutics Cut by Analyst
ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of ProQR Therapeutics in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biopharmaceutical
ProQR Therapeutics stock logo
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $602,000 in ProQR Therapeutics (NASDAQ:PRQR)
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 227,020 shares of the biopharmaceutical company's sto
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts
Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by DAFNA Capital Management LLC
DAFNA Capital Management LLC boosted its position in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 73.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,567,561 shares of the biopharmaceutical company's stock after buying a
ProQR: Q1 Earnings Snapshot
ProQR: Q1 Earnings Snapshot
ProQR Therapeutics stock logo
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC bought a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,181,413 shares of the biopharmaceut
ProQR Therapeutics stock logo
Equities Analysts Set Expectations for PRQR FY2025 Earnings
ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for ProQR Therapeutics in a research note issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the biopharmaceutical company will post earnings per sha
ProQR Therapeutics stock logo
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday
ProQR Therapeutics (NASDAQ:PRQR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-proqr-therapeutics-stock/)
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Boothbay Fund Management LLC
Boothbay Fund Management LLC increased its holdings in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 143.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 260,276 shares of the biopharmaceutical company's stock
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald started coverage on ProQR Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $8.00 target price for the company.
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Evercore ISI
Evercore ISI initiated coverage on shares of ProQR Therapeutics in a report on Tuesday. They set an "outperform" rating and a $5.00 target price for the company.
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Stock Position Boosted by Adage Capital Partners GP L.L.C.
Adage Capital Partners GP L.L.C. grew its stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 164.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,602,280 shares of the biopharmaceutic
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Decline in Short Interest
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 843,100 shares, a drop of 17.3% from the March 15th total of 1,020,000 shares. Based on an average daily trading volume, of 476,600 shares, the short-interest ratio is currently 1.8 days. Approximately 1.1% of the company's stock are sold short.
ProQR Therapeutics stock logo
Walleye Capital LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR)
Walleye Capital LLC acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 451,303 shares of the biopharmaceutical company's stock, valued
ProQR Therapeutics stock logo
575,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Altium Capital Management LLC
Altium Capital Management LLC acquired a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 575,000 shares of the biopharmaceutical company's stock, val
ProQR Therapeutics stock logo
2,825,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC bought a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,825,000 shares of the biopharmaceutical company's stock, valued at approxi
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Brokerages
Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received a consensus rating of "Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a s
ProQR Therapeutics appoints Hom as CFO, Lopez as CMO
ProQR Therapeutics stock logo
FY2025 Earnings Estimate for PRQR Issued By Chardan Capital
ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Research analysts at Chardan Capital raised their FY2025 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharma
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are currently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating t
ProQR Therapeutics stock logo
Privium Fund Management B.V. Decreases Stake in ProQR Therapeutics (NASDAQ:PRQR)
Privium Fund Management B.V. reduced its position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,985,633 shares of the biopharmaceutical company's stock after sel
ProQR Therapeutics stock logo
Platinum Investment Management Ltd. Purchases Shares of 1,538,247 ProQR Therapeutics (NASDAQ:PRQR)
Platinum Investment Management Ltd. purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,538,247 shares of the biopharmaceutical company's st
ProQR Therapeutics stock logo
ProQR Therapeutics' (PRQR) Buy Rating Reiterated at Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday.
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $12.00
HC Wainwright lifted their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday.
ProQR Therapeutics stock logo
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.
ProQR Therapeutics files to sell 3.52M ordinary shares for holders
Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

PRQR Media Mentions By Week

PRQR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PRQR
News Sentiment

1.46

1.03

Average
Medical
News Sentiment

PRQR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PRQR Articles
This Week

5

2

PRQR Articles
Average Week

Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PRQR) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners